A Johnson & Johnson subsidiary blamed for male breast development and other injuries in hundreds of Risperdal lawsuit filings has announced the launch of a new global health program, the company reported this month.
According to an article published Jan. 22nd online on 4-Traders.com, Janssen Pharmaceuticals, Inc. plans to spearhead an initiative to create new access strategies for distributing services and medicines in countries with limited resources.
Medicines will be more affordable through the program, officials say, which will expand off Janssen’s Global Access and Partnerships Program (GAPP) to ensure that patients in these areas receive access to the company’s HIV medicines.
“To solve today’s greatest public health challenges, it’s essential that we emphasize the needs of the developing world in equal measure to those of the developed world,” said the Worldwide Chairman of Janssen and Chief Scientific Officer of Johnson & Johnson.
Janssen’s recent global efforts are being announced as the company continues to face more and more lawsuits brought on behalf of men and young boys who allege Risperdal gynecomastia, or male breast growth complications after taking the drug. As of January 2014, over 200 cases alleging the companies’ failure to adequately warn about side effects associated with the medication were pending in Pennsylvania’s Philadelphia Court of Common Pleas.
The dust is also beginning to settle on a Risperdal settlement agreement between Janssen and its parent company, Johnson & Johnson and the U.S. Department of Justice. The settlement was reached after Johnson & Johnson paid more than $2.5 million to resolve civil and criminal charges related to its off-label marketing of Risperdal and certain other medications. According to the federal government, Johnson & Johnson promoted Risperdal, a drug approved by the U.S. Food and Drug Administration (FDA) to treat bipolar disorder and schizophrenia in adults and adolescents, as well as irritability in children with autism, for uses not approved by the federal agency. Children were marketed Risperdal before it was approved for pediatric uses in 2006, as were elderly patients with dementia.
Call a Risperdal attorney at Bernstein Liebhard LLP to find out more about gynecomastia and other side effects of this anti-psychotic medication. Contact the Firm directly at .